Table 3 Toxicity according to CDA activity (number of patients)

From: Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study

 

Low activity ≤7.2 U/mg (61 pts)

High activity > 7.2 U/mg (60 pts)

 

Grade 3–4 (%)

Grade 3–4 (%)

Haematological (all events)

18 (29.5)

13 (22)

 Anaemia

6 (9.8)

5 (8.3)

 Neutropenia

20 (32)

16 (26.6)

 Thrombocytopenia

9 (14.7)

7 (11.6)

Non-haematological (all events)

10 (16)

10 (17)

 Vomiting

4 (6.5)

3 (5)

 Nausea

3 (4.9)

4 (6.6)

 Weakness

3 (4.9)

3 (5)

 Paraesthesia

0

0

 Tinnitus

0

0

 Hepatic toxicity

0

0

 Renal toxicity

0

0

  1. Most patients had several haematological toxicities and only the worst toxicity grade among all the toxicities for each patient was reported
  2. NOTE. Data on haematological and non-haematological toxicity were available from 121 patients. Considering the total number of toxicities in each CDA subgroup, no significant association was observed with the Pearson-χ2 two-sided test with continuity correction.